Kyle W. H. Chan
Directeur Technique/Scientifique/R&D chez BioTheryX, Inc.
Profil
Kyle W.
H.
Chan is the founder of NovaDx Ventures Corp.
founded in 1983.
He is currently a Director at TheraVasc, Inc. and the Chief Technology Officer at BioTheryX, Inc. since 2007.
He previously worked as a Senior Director-Discovery Research at Celgene Corp.
Dr. Chan has an undergraduate degree from Occidental College and a doctorate from the University of Illinois.
Postes actifs de Kyle W. H. Chan
Sociétés | Poste | Début |
---|---|---|
TheraVasc, Inc.
TheraVasc, Inc. Pharmaceuticals: MajorHealth Technology TheraVasc, Inc. operates as a pharmaceutical company. It develops treatments for various chronic medical diseases and drugs for unserved vascular disease markets. The company was founded by Anthony Giordano, Christopher Kevil and James Douglas Boudreaux in 2008 and is headquartered in Cleveland, OH. | Directeur/Membre du Conseil | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Directeur Technique/Scientifique/R&D | 01/07/2007 |
Anciens postes connus de Kyle W. H. Chan
Sociétés | Poste | Fin |
---|---|---|
NOVADX VENTURES CORP. | Fondateur | - |
CELGENE | Corporate Officer/Principal | - |
Formation de Kyle W. H. Chan
Occidental College | Undergraduate Degree |
University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 4 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
NovaDx Ventures Corp.
NovaDx Ventures Corp. CoalEnergy Minerals NovaDx Ventures Corp. is a mining investment company. It engages in the exploration, development, and recovery of coal reserves. The company was founded on September 19, 1983 and is headquartered in Knoxville, TN. | Energy Minerals |
TheraVasc, Inc.
TheraVasc, Inc. Pharmaceuticals: MajorHealth Technology TheraVasc, Inc. operates as a pharmaceutical company. It develops treatments for various chronic medical diseases and drugs for unserved vascular disease markets. The company was founded by Anthony Giordano, Christopher Kevil and James Douglas Boudreaux in 2008 and is headquartered in Cleveland, OH. | Health Technology |